Clinical trials
Prostate Cancer Metastatic Disease clinical trials
Below are recruiting prostate cancer metastatic disease clinical trials, each written for real people, not researchers. We’re tracking 591 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05759728RecruitingPhase 1/Phase 2
LGR5-targeted CAR-T for metastatic colorectal cancer
This early-phase study tests an autologous CAR-T cell treatment that is designed to recognize LGR5 on colorectal cancer cells. It aims to shrink metastatic colorectal cancer that has already been treated with up to two prior standard chemotherapy regimens.
Adelaide, South AustraliaAges 18 years+ - NCT06008119RecruitingPhase 3
Targeted pill combination for BRAF-mutated metastatic colorectal cancer
This study tests a combination of two targeted pills (tunlametinib and vemurafenib) for people with metastatic colorectal cancer that has a specific gene change (BRAF V600E) and whose cancer has grown after at least one prior treatment. The goal is to see if this drug combination can shrink tumors or slow cancer growth.
Beijing, Beijing MunicipalityAges 18–70 - NCT07221825Recruiting
Radium-223 imaging study for men with prostate cancer
This study uses a special type of scan (quantitative SPECT) to measure how Radium-223 (Xofigo) works in your bones. It helps doctors better understand treatment for prostate cancer that has spread to the bones.
St Louis, MissouriAges 18 years+ - NCT02997709Recruiting
Collecting prostate cancer body marker samples during treatment
This study collects and measures “biomarkers” (measurable signs in the body) from people with prostate cancer who are about to have surgery or radiation. The goal is to understand how prostate cancer behaves during treatment, which may help improve care in the future.
Miami, FloridaAges 30 years+ - NCT04035642Recruiting
Single high-dose MRI-guided radiation for intermediate prostate cancer
This trial tests whether a single, image-guided radiation treatment can treat intermediate-risk prostate cancer while better protecting the urethra (the urine tube). It may help patients get effective cancer control with potentially fewer urinary side effects, depending on the results.
LisbonAges 18 years+ - NCT05304858Recruiting
Study of prostate cancer spread using biopsy and lab tests
This trial studies the “microenvironment” around prostate cancer metastases, using specimens taken during biopsy and other scans. It may help researchers understand what drives prostate cancer spread and improve future treatment choices.
New York, New YorkAges 18 years+ - NCT05776524RecruitingPhase 2
Radiofrequency heat treatment for pancreas cancer spread to other organs
This Phase 2 trial tests whether a device that delivers carefully timed “radiofrequency heat” through the body can slow or control metastatic (spread) pancreatic cancer. You may qualify if you have newly diagnosed metastatic pancreatic cancer and can meet safety and blood-test requirements.
Winston-Salem, North CarolinaAges 18 years+ - NCT06594887Recruiting
Rectal spacer use during proton therapy for prostate cancer
This trial tests how well a rectal spacer works when you get proton beam therapy for prostate cancer. The spacer is a gel placed between your prostate and rectum to protect healthy tissue.
Somerset, New JerseyAges 18 years+ - NCT07042685RecruitingPhase 2
5-FU and Fruquintinib for advanced colorectal cancer
This trial tests a combination of two drugs (5-FU and fruquintinib) in people with advanced colorectal cancer that cannot be removed by surgery or has spread. It is for those who have not had chemotherapy before.
Houston, TexasAges 18 years+ - NCT07189598Recruiting
High-dose radiation therapy for high-risk prostate cancer
This trial tests whether giving a higher dose of radiation therapy (called SBRT) can safely and effectively treat high-risk prostate cancer that hasn't spread. It's for men who have not yet been treated for their cancer.
RennesAges 18 years+ - NCT05267626RecruitingPhase 1/Phase 2
AU-007 antibody for hard-to-remove or spread skin and lung cancers
This trial tests AU-007, an antibody that targets the IL-2 pathway, in people with certain advanced skin (melanoma) or lung (NSCLC) cancers. It’s designed for cancers that have already progressed after prior immune and other treatments, to see if AU-007 can shrink tumors or control disease.
Miami, FloridaAges 18 years+ - NCT06834204Enrolling by invitation
Better care coordination for cancer survivors
This study tests a program to improve communication between your cancer team and your regular doctor. If you have heart or diabetes risks and you're being treated for breast, prostate, bladder, or endometrial cancer, this trial may help coordinate your care.
New Brunswick, New JerseyAges 18 years+ - NCT06759701RecruitingEarly Phase 1
Weight loss drug before prostate cancer surgery pilot study
This study tests if taking tirzepatide (a weight loss medicine) before prostate removal surgery is safe and helpful for overweight men with intermediate-risk prostate cancer. It aims to see if losing weight can improve surgery outcomes.
Houston, TexasAges 18 years+ - NCT06346197RecruitingPhase 3
Immunotherapy combo for advanced MSI-H stomach/esophageal cancer
This trial tests a combination of immune checkpoint inhibitors (nivolumab, botensilimab, and balstilimab) plus chemotherapy for people with advanced stomach or esophageal cancer that has a specific genetic instability (MSI-H/dMMR) and expresses PD-L1. It may be an option for those who haven't had prior immunotherapy or chemotherapy for advanced disease.
BrestAges 18 years+ - NCT04610372Recruiting
Targeted radiation plus hormone therapy for prostate cancer spread
This study compares different ways of giving radiation (SABR or brachytherapy) along with long-term hormone therapy for men whose prostate cancer has spread to a limited number of spots in the body. It aims to see which radiation approach controls the cancer as well as possible while keeping quality of life in mind.
Kelowna, British ColumbiaAges 18 years+ - NCT04363164RecruitingPhase 2
Testosterone then enzalutamide to stop prostate cancer spread
This Phase 2 trial tests whether giving testosterone first, then enzalutamide (a prostate cancer hormone-blocking pill), can slow or prevent worsening metastatic prostate cancer. It is designed for men whose cancer progressed despite ongoing hormone-suppression treatment.
San Diego, CaliforniaAges 18–90 - NCT06585007RecruitingPhase 3
Radiation for limited cancer growth in castration-resistant prostate cancer
This trial tests whether giving focused radiation to limited areas of cancer growth (up to 3 spots) can help control the disease in men with castration-resistant prostate cancer. You may be eligible if your cancer is growing slowly and you are already on hormone therapy.
LeuvenAges 18 years+ - NCT07240857Enrolling by invitationEarly Phase 1
CAR-T cell injection for advanced prostate cancer
This trial tests a new treatment called ACT#001 CAR-T cells, given as a local injection, for prostate cancer that has stopped responding to hormone therapy. It aims to see if this therapy is safe and can help shrink tumors.
Hangzhou, ZhejiangAges 18 years+ - NCT04861194Recruiting
Test treatment plans to preserve erections during prostate radiation
This trial studies ways to help preserve erectile function while you receive radiation treatment for prostate cancer. It may help by aiming to protect erections, especially for people at low to intermediate risk.
Utrecht, UtrechtAges 18 years+ - NCT05997615RecruitingPhase 1
Study of VIR-5500 for advanced prostate cancer
This trial tests VIR-5500 (AMX-500), a new targeted treatment, in men with prostate cancer that has spread and stopped responding to standard therapies. The goal is to see if it is safe and if it may help shrink or slow the cancer.
Palo Alto, CaliforniaAges 18 years+ - NCT07205783Enrolling by invitation
Comparing surgery and radiation for early prostate cancer
This trial compares two standard treatments for prostate cancer that hasn't spread: surgery to remove the prostate (radical prostatectomy) and radiation therapy (curative radiotherapy). It looks back at past patients to see which treatment worked better.
SohagAges 40 years+ - NCT06085664RecruitingPhase 1/Phase 2
Immunotherapy before prostate cancer surgery
This trial tests a new immunotherapy drug (REGN5678) given before surgery to men with high-risk prostate cancer that hasn't spread. The goal is to see if the drug can shrink or control the cancer before the prostate is removed.
Houston, TexasAges 18 years+ - NCT06367972RecruitingPhase 2/Phase 3
Extending systemic therapy with local treatment for limited cancer growth
This trial tests whether adding local treatments like radiation or surgery to standard therapy can help control cancer that has started to grow in just a few spots. It is for people with certain advanced cancers that have 1 to 5 growing lesions that can be treated locally.
Houston, TexasAges 18 years+ - NCT06470243RecruitingPhase 3
Adding carboplatin to cabazitaxel for advanced prostate cancer
This study tests whether adding a chemotherapy drug called carboplatin to another chemotherapy called cabazitaxel works better than cabazitaxel alone for men with advanced prostate cancer that has spread and no longer responds to hormone therapy. All participants must have already had docetaxel chemotherapy.
Fayetteville, ArkansasAges 18 years+
Hear when a new Prostate Cancer Metastatic Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for prostate cancer metastatic disease?
- Yes. Clin2 currently lists 591 recruiting prostate cancer metastatic disease studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a prostate cancer metastatic disease trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a prostate cancer metastatic disease trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Metastatic Castration-resistant Prostate Cancer
- Metastatic Prostate Cancer
- Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
- Metastatic Castrate Resistant Prostate Cancer (mCRPC)
- Metastatic Castration-Resistant Prostate Cancer Patients
- Non-metastatic Castration-resistant Prostate Cancer
- Metastatic Breast Cancer
- Metastatic Colorectal Cancer
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.